RxDoctor Payments Data

Dylan Zini, MD

Family Medicine · St Petersburg, FLNPI 1144632290

Payments from drug & device makers

$1,827in general payments, 2019–2025

Across 94 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$302
  • AbbVie$274
  • Lilly USA, LLC$232
  • AstraZeneca$196
  • Amgen$159
  • Pfizer$132
  • plus $532 from 14 others

What the payments were for

  • Food & beverage$1,827100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,827 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$96,188
Medicare patients
274
Services billed
1,083

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban93$122,399
JardianceEmpagliflozin59$90,014
FarxigaDapagliflozin Propanediol72$87,081
MounjaroTirzepatide23$45,293
XareltoRivaroxaban32$43,258
TrulicityDulaglutide30$40,930
OzempicSemaglutide33$38,206
CreonLipase/Protease/Amylase23$38,063
WegovySemaglutide19$25,110
JanuviaSitagliptin Phosphate16$21,566
Spiriva HandihalerTiotropium Bromide24$18,242
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$14,843
Insulin Lispro Kwikpen U-100Insulin Lispro12$7,685
Incruse ElliptaUmeclidinium Bromide15$6,741
Doxepin Hcl42$6,650

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$132$122,39993 claims
AstraZenecaFarxiga$196$87,08172 claims
Lilly USA, LLCMounjaro, Trulicity$232$86,22253 claims
Novo NordiskOzempic, Wegovy$302$63,31752 claims
Johnson & JohnsonXarelto$21$43,25832 claims
AbbVieCreon$274$38,06323 claims
GSKTrelegy Ellipta, Incruse Ellipta$79$21,58434 claims
MerckJanuvia$40$21,56616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in St Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →